METHODS: In this proposed type 2 hybrid implementation-effectiveness trial, where the primary goal is equitable reach to families to reduce asthma disparities, we will compare two different packages of implementation strategies to deliver BACK across four Colorado regions. The two implementation packages to be compared are: 1) standard set of implementation strategies including Tailor and Adapt to context, Facilitation and Training termed, BACK-Standard (BACK-S); 2) BACK-S plus an enhanced implementation strategy, that incorporates network weaving with community partners and consumer engagement with school families, termed BACK-Enhanced (BACK-E). Our evaluation will be guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, including its Pragmatic Robust Implementation Sustainability Model (PRISM) determinants of implementation outcomes. Our central hypothesis is that our BACK-E implementation strategy will have significantly greater reach to eligible children/families than BACK-S (primary outcome) and that both BACK-E and BACK-S groups will have significantly reduced asthma exacerbation rates (\"attacks\") and improved asthma control as compared to usual care.
CONCLUSIONS: We expect both the BACK-S and BACK-E strategy packages will accelerate dissemination of our BACK program across the state - the comparative impact of BACK-S vs. BACK-E on reach and other RE-AIM outcomes may inform strategy selection for scaling BACK and other effective school-based programs to address chronic illness disparities.
BACKGROUND: Clinicaltrials.gov identifier: NCT06003569, registered on August 22, 2023, https://classic.
RESULTS: gov/ct2/show/NCT06003569 .
方法:在这项拟议的2型混合实施-有效性试验中,主要目标是公平接触家庭以减少哮喘差异,我们将比较两个不同的一揽子实施策略,以在科罗拉多州的四个地区提供回报。要比较的两个实施包是:1)实施策略的标准集,包括裁缝和适应上下文,便利和培训称为,BACK-标准(BACK-S);2)BACK-S加上增强的实施策略,包括与社区合作伙伴的网络编织和与学校家庭的消费者参与,称为BACK-增强(BACK-E)。我们的评估将由Reach指导,有效性,收养,实施,和维护(RE-AIM)框架,包括其务实稳健的实施可持续性模型(PRISM)实施结果的决定因素。我们的中心假设是,与BACK-S(主要结果)相比,我们的BACK-E实施策略对符合条件的儿童/家庭的影响要大得多,并且与常规护理相比,BACK-E和BACK-S组将显着降低哮喘加重率(“发作”)并改善哮喘控制。
结论:我们预计BACK-S和BACK-E战略包将加速我们的BACK计划在全州的传播-BACK-S与BACK-S的比较影响BACK-E对可达性和其他RE-AIM结果的选择可能会为扩展BACK和其他有效的基于学校的计划提供策略选择,以解决慢性病差异。
背景:Clinicaltrials.gov标识符:NCT06003569,于2023年8月22日注册,https://classic。
结果:gov/ct2/show/NCT06003569。